0 followers
Eidos Therapeutics, a subsidiary of BridgeBio Pharma, is developing AG10 as a targeted therapeutic for transthyretin amyloidosis. The company’s singular mission is to improve and prolong the lives of patients suffering from this disease. Launched in 2016 after years of research supported by Stanfor... Read more
Neil Kumar
SpringWorks Therapeutics
6 followers
REVOLUTION Medicines
5 followers
C4 Therapeutics
5 followers
Summit Therapeutics
5 followers
Inari
3 followers
Dyne Therapeutics
3 followers
Beta Bionics
3 followers
Rigel Pharmaceuticals
3 followers
Precigen
3 followers
PureTech Health
3 followers
Arcturus Therapeutics
2 followers
Explore companies